Label Reduces Parenteral Dispensing Errors - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Label Reduces Parenteral Dispensing Errors

Equipment and Processing Report

Schreiner MediPharm's Pharma-Comb Single Wrap (SW) label helps reduce the likelihood of parenteral dispensing errors through a combination of elements that enhance instructional clarity. The new solution is particularly suited for labeling small containers for single-dose applications, such as ampoules and vials.

To minimize the risk of dangerous medication errors, the FDA issued a Draft Guidance in April 2013 for the design of pharmaceutical labels and packaging that encourage reliable and simple dispensing. Schreiner MediPharm’s Pharma-Comb SW labels meet these recommendations and assist healthcare professionals in properly dispensing medicines.

Pharma-Comb SW labels provide sufficient space for legally required information, as well as for variable data inscription and barcode printing.  Product information is easy to read, and barcode scanning is simple. The reverse side of the detachable section is designed so it can be applied to a syringe in a flag-like fashion that leaves graduation lines uncovered. For greater ease of use when wearing gloves, the detachable part slightly lifts for easy peel-off upon label opening.

“In its draft guidance, the FDA cites the potential value of transferrable labels for injectable medications, emphasizing that the filling of solutions into unlabeled disposable syringes carries a particularly high risk of medication errors, namely those involving the wrong drug or strength,” said Gene Dul, president of Schreiner MediPharm US, in a press release.  “The Pharma-Comb Single Wrap labels help avoid such instances by equipping the primary container with a label that includes an integrated peel-off section. This detachable part is instantly available at the point of product preparation and can be easily and reliably attached to an unmarked syringe.”

Source: Schreiner MediPharm

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Equipment and Processing Report,
Click here